The pharmaceutical giant Pfizer will invest more than 520 million euros in France over five years, particularly in the fight against Covid-19, its CEO announced on Monday morning.
The American group has thus signed a letter of intent with the pharmaceutical laboratory Novasep, based in Mourenx (Pyrénées-Atlantiques).
Novasep will produce the active ingredient (API) of Pfizer's Covid-19 treatment, Paxlovid.
"The group thus joins Pfizer's global supplier network, which will manufacture up to 120 million boxes [of Paxlovid] for patients worldwide by the end of 2022," Novasep said in a statement.
The Mourenx site could produce the active ingredient of Paxlovid from the third quarter of 2022.
To date, the group plans to recruit more than 40 additional employees dedicated to this project at the Mourenx site.
A treatment that has shown a positive impact on patient hospitalization
"We are proud to contribute to the manufacture of this drug, which has shown during clinical trials a positive impact on the hospitalization of at-risk patients suffering from Covid-19," said Novasep CEO Michel Spagnol in a press release. .
This contract also validates our investment strategy and our focus on small molecules.
This treatment, if taken in the first days of the appearance of symptoms, would reduce the chances of contracting a serious form leading to hospitalization by 90%.
Coronavirus: Pfizer confirms very positive results for its anti-Covid-19 pill
Coronavirus: Monoclonal antibodies, antiviral tablets… Five promising treatments against Covid-19 scrutinized
Share on Messenger
Share on Facebook
Share on Twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
A fault ?